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SUMMARY
Therapeutics such as lapatinib that target ERBB2 often provide initial clinical benefit but 
resistance frequently develops. Adaptive responses leading to lapatinib resistance involve 
reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and 
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transcriptional upregulation and activation of multiple tyrosine kinases. The heterogeneity of 
induced kinases prevents their targeting by a single kinase inhibitor, underscoring the challenge of 
predicting effective kinase inhibitor combination therapies. We hypothesized that to make the 
tumor response to single kinase inhibitors durable, the adaptive kinome response itself must be 
inhibited. Genetic and chemical inhibition of BET bromodomain chromatin readers suppresses 
transcription of many lapatinib-induced kinases involved in resistance including ERBB3, IGF1R, 
DDR1, MET, and FGFRs, preventing downstream SRC/FAK signaling and AKT reactivation. 
Combining inhibitors of kinases and chromatin readers prevents kinome adaptation by blocking 
transcription, generating a durable response to lapatinib and overcoming the dilemma of 
heterogeneity in the adaptive response.
INTRODUCTION
The human epidermal growth factor receptor 2 (HER2/ERBB2) is a member of the EGFR/
ERBB family of receptor tyrosine kinases (RTKs). The ERBB2 oncogene is amplified or 
overexpressed in roughly 25% of breast cancers and serves as the primary driver of tumor 
cell growth in the majority of these cancers. Clinical trials indicate that ERBB2 “addiction” 
is fundamental to the behavior of these tumors and targeting ERBB2 has proven to be an 
effective treatment in a subset of ERBB2+ breast cancer patients. Approved ERBB2-
targeting therapies include the monoclonal antibodies trastuzumab, pertuzumab, and 
trastuzumab-DM1, an antibody drug conjugate, in addition to the ATP-competitive EGFR/
ERBB2 inhibitor lapatinib. However, even with initial dramatic clinical responses to these 
therapies as single agents or in combination, patients frequently relapse as resistance 
develops. The preferred dimerization partner of ERBB2 is ERBB3/HER3, and a major 
mechanism of lapatinib resistance is due to transcriptional and post-translational 
upregulation of ERBB3 (Amin et al., 2010; Garrett et al., 2011). Multiple other kinases 
contribute to the resistant phenotype as well, including IGF1R, MET, FGFR2, FAK, and 
SRC family kinases (Azuma et al., 2011; Huang et al., 2011; Rexer and Arteaga, 2012).
Characteristically, tumors have a remarkable resiliency toward kinase-directed therapeutics, 
capable of rewiring their signaling networks to evade effects of the drug and develop 
resistance. Targeting specific signaling nodes crucial for tumor growth, such as PI3K, AKT, 
mTOR, BRAF, and MEK elicits adaptive kinome responses that upregulate alternative 
kinase signaling networks or reactivate the targeted pathway to overcome inhibitor treatment 
(Chandarlapaty et al., 2011; Duncan et al., 2012; Rodrik-Outmezguine et al., 2011; Serra et 
al., 2011; Sun et al., 2014). This “adaptive kinome reprogramming” is mechanistically based 
on the disruption of feedback and feedforward regulatory loops that serve to bypass the 
inhibition and rapidly generate resistance to targeted therapies. Adaptive bypass responses in 
tumor cells are a major reason that kinase inhibitors often do not have durable responses in 
the treatment of cancer patients.
To understand these bypass mechanisms toward ERBB2 inhibition, we investigated 
lapatinib-induced kinome adaptation in a panel of ERBB2+ cell lines using a chemical 
proteomics method. We find the adaptive kinome response to lapatinib involves the 
activation of multiple RTKs, SRC family kinases, FAK, and members of other intracellular 
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networks downstream of RTKs. We additionally identify significant heterogeneity in this 
response among different ERBB2+ cell lines. Multiple kinases contribute to escape from 
lapatinib-mediated growth inhibition, consistent with a shift in dependency to alternative 
signaling nodes in addition to ERBB2. This prevents their targeting by a single kinase 
inhibitor, underscoring the difficulty of choosing the most effective kinase inhibitor 
combinations to treat ERBB2+ tumors. These results suggest that chasing combination 
therapies with multiple kinase inhibitors has a poor likelihood of success. We approached 
this problem with the hypothesis that lapatinib would be more durable in inhibiting ERBB2+ 
cell growth if we could block the adaptive reprogramming response itself. We target 
chromatin readers involved in transcriptional upregulation of RTKs that drive the adaptive 
signaling networks responsible for lapatinib resistance. By inhibiting the onset of the 
adaptive response, we achieve durable growth inhibition greater than that observed by 
targeting several different kinases with inhibitors. Our studies demonstrate that inhibiting 
the adaptive kinome response provides a method to address the heterogeneity in kinome 
adaptation and a mechanism to prevent resistance to kinase inhibitors.
RESULTS
Lapatinib induces dynamic adaptive kinome responses in ERBB2+ breast cancer cells
We used Multiplexed Inhibitor Beads coupled with Mass Spectrometry (MIB/MS) to 
quantitatively measure dynamic changes in kinase activity on a proteomic scale (Figure 1A) 
(Duncan et al., 2012). SKBR-3 and BT474 luminal ERBB2+ breast cancer cells were treated 
with lapatinib for 4, 24, and 48 h (Figures 1B, S1A, S1B). The kinome of SKBR-3 cells is 
remarkably responsive to lapatinib with many kinases displaying enhanced MIB-binding, 
indicative of increased kinase activity relative to untreated cells. Lapatinib induces growth 
inhibition and there is a concomitant time-dependent loss of MIB-binding of cell cycle-
regulating kinases, correlating with inhibition of their kinase activity. Loss of ERBB2 and 
EGFR MIB-binding is observed in both SKBR-3 and BT474 cells at 4 h, but in SKBR-3 
cells, ERBB2 binding has returned to untreated levels after 48 h, indicating reactivation of 
ERBB2 (Figures 1B, 1C). In BT474 cells, ERBB2 remains inhibited at 48 h. ERBB3 
binding to MIBs increases within 24 h, consistent with ERBB3 upregulation in response to 
lapatinib (Amin et al., 2010). The time course illustrates the dynamic behavior of the kinome 
with kinases having temporal differences in regulation of their activity (Figures 1D, 1E, 
S1A). EGFR displays rapid and sustained loss of MIB-binding, while most inhibited kinases 
demonstrate a progressive loss of MIB-binding over 48 h of lapatinib treatment. Some 
kinases display similar reactivation dynamics to ERBB2 (IGF1R, PTK6, ADCK1), 
suggesting they operate in a common regulatory network. Others such as ERBB3, AKT1, 
DDR1, and ARAF are initially inhibited but reactivate with greater MIB-binding than their 
baseline control activity. Kinases such as FGFR2 respond with increased activity within 4 h 
while other tyrosine kinases (TKs) such as FRK, YES, FAK1, and JAK1 become 
progressively more activated, suggesting they are regulated downstream of the kinases 
driving the initial adaptive kinome response. Western blots confirm MIB/MS results, with 
inhibition of ERBB family phosphorylation and downstream signaling (AKT, ERK1/2) at 4 
h and reactivation by 48 h (Figure 1F). Total protein levels of EGFR, ERBB2, ERBB3, 
DDR1, FRK, and PKCδ increase over time, along with activation loop phosphorylation of 
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FAK and SRC family kinases (SFKs). STAT3 activating phosphorylation is induced by 
lapatinib, downstream of JAK signaling and independent of SFK signaling (Figure S1C). 
Addition of a higher dose of lapatinib (1μM) after 48 h inhibits partial reactivation of EGFR, 
ERBB2 and ERBB3 phosphorylation, but effects on downstream FAK/SFK/AKT/ERK 
signaling are limited.
BT474 cells generate a less-robust adaptive response with more kinases inhibited than 
activated (Figures 1G, S1B). BT474 cells display a progressive loss of MEK/ERK MIB 
binding, but a rebound in AKT signaling similar to SKBR-3 cells, with initial inhibition of 
AKT1 and overall increase in AKT2 MIB-binding (Figures 1B, 1G). Interestingly, 
MEK/ERK MIB-binding in SKBR-3 cells is seemingly unchanged by short-term treatment 
with lapatinib in the 4 h MIB/MS profile, suggesting additional inputs regulate their activity. 
Western blots of BT474 cells treated with lapatinib demonstrate little reactivation of ERBB2 
and ERBB3, with progressively increasing IGF1R and INSR phosphorylation and total 
levels, SFK phosphorylation, and a partial return of AKT and ERK1/2 activity (Figure 1H).
MIB/MS defines heterogeneity in the adaptive kinome response to lapatinib
Across four independent MIB/MS runs for SKBR-3 cells, we defined a signature of kinases 
with highly statistically significant changes in MIB-binding after 48 h lapatinib treatment 
(Figure 2A). Kinases with enhanced MIB-binding (increased activity) include the RTKs 
DDR1, EPHB3, and FGFR2, non-receptor TKs JAK1, FAK1, and SFKs FRK and YES, and 
multiple kinases involved in cytoskeletal regulation (MYLK3, NEK9, MARK2, MRCKB, 
LIMK2). The CMGC kinases CDK5, -10, and -17, and AGC kinases KPCD (PKCδ) and 
KS6A5 (RSK5) are also activated. PRKDC (DNA damage sensor), STK3 (HIPPO pathway/
pro-apoptotic signaling), and AAPK1 (AMP-activated) are activated by multiple growth-
inhibiting treatments and likely represent a stress-induced kinase response. Kinases with loss 
of MIB binding within the signature include multiple cell cycle regulating kinases, RTKs 
EGFR and EPHA2, and serine/threonine kinases KC1A, RIPK2, M3K2, and KS6A1 
(RSK1). For BT474 cells, the 48 h MIB/MS signature defines a very different lapatinib 
response, with activation of INSR, PRPK (TP53-regulating kinase), ULK3 (autophagy, 
Hedgehog pathway), and KS6A4 (RSK4). Opposite from SKBR-3 cells, DDR1, FRK, 
NEK9, and cytoskeleton-regulating kinases (MARK3 and LIMK1) are inhibited (Figure 
2A). Of activated kinases, only YES, KS6A5, PRKDC, and STK3 are common between 
SKBR-3 and BT474 cells.
MIB/MS was performed for three additional ERBB2-amplified cell lines after 48 h lapatinib 
treatment: luminal HCC1419 cells are highly sensitive to lapatinib-induced growth arrest, 
while basal-like HCC1954 and luminal MDA361 cells are more resistant. HCC1954 and 
MDA361 harbor activating PIK3CA mutations (H1047R and E545K, respectively) and 
display resistance to trastuzumab. The kinome of HCC1954 cells is very responsive with 
activation of multiple RTKs, PKC isoforms, and CAMKs. In contrast, the kinome of 
MDA361 cells is mostly suppressed by lapatinib with INSR and IGF1R the only RTKs with 
statistically significant increases in MIB binding (Figure 2A). HCC1419 cells are 
intermediate in their adaptive response, with four TKs significantly activated: DDR1, INSR, 
FAK1 and FRK. Across cell lines, multiple induced kinases are known to modulate or act 
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downstream of ERBB signaling, including SFKs, FAK1, JAK1, CSK, CDK5, and PKCδ, 
emphasizing an addiction to ERBB-driven signaling networks (Allen-Petersen et al., 2014; 
Li et al., 2003). It was unexpected that the lapatinib adaptive response would demonstrate 
such heterogeneity across multiple kinase subfamilies in five ERBB2+ cell lines (Figure 2B, 
TKs; Figure S2A, other subfamilies). The responsiveness of the kinome does not seem to 
correlate with EGFR/ERBB2 expression or activation level or the dependency on different 
ERBB family members as measured by RNAi analysis (Figures S2B-C).
The RTK family displays significant variability in activity and response across the five cell 
lines, but IGF1R/INSR is commonly activated and EPHA2 commonly inhibited in all lines 
(Figure 2B). Among non-receptor TKs, multiple cell lines activate FRK, FAK1, and TYK2. 
SKBR-3 and HCC1954 share a robust activation of most TKs captured by MIBs. 3x3 self-
organizing map (SOM) clustering identifies common kinase behavior between several lines, 
including induction of PRKDC, STK38, NEK9, FRK, STK3, and DDR1 (Figure S3A-B). A 
cluster preferentially induced in HCC1954 includes stress response kinases (MK09, MK11, 
MK14, STK24), CSK22 (CK2α), KCC2G (CAMK2G), KPCD2, and TKs ACK1 and PTK6 
(Figure S3C). Commonly-inhibited kinases among the five cell lines include cell cycle-
regulating kinases as well as KS6B1 (p70 S6 kinase) (Figure S3D). To understand the 
variation in kinome response between cell lines, we utilized principal component analysis 
(PCA) (Figure 2C). Principal component 1 (PC1) accounts for the majority of the variation 
and separates kinases that are commonly suppressed (STK6, PMYT1, CDK1, EPHA2, 
CDK4) from those that are primarily induced (PRKDC, INSR, DDR1) among cell lines. 
Kinases driving variation between cell lines in PC2 and PC3 agree with differences observed 
in 48 h MIB/MS signatures (Figure 2A) and SOM analysis (Figure S3A-D), and provide a 
statistical measure of the heterogeneity in the kinome response. These kinases include 
DDR1, FRK, KPCD, KT3K, CDK5, PTK6, PRPK and KS6A4.
mRNA sequencing (RNAseq) indicates 18-20% of the transcriptome is modulated at least 2-
fold after 48h lapatinib treatment in SKBR-3 and BT474 cells (Figure 2D). Gene ontology 
terms enriched in commonly upregulated genes involve regulation of glucose homeostasis 
and transcription, consistent with a reactivation of AKT signaling networks and 
reorganization of a significant portion of the transcriptome (Figure 2E). Kinases commonly 
upregulated 2-fold or more between SKBR-3 and BT474 cells include RTKs INSR, ERBB3, 
and ERBB4, the cytoskeleton-regulating kinases TBCK, DCLK2, and TTBK2, and DYRK1B 
– a modulator of FOXO transcription (Figure 2F). ERBB2, PTK7 and DDR1 in SKBR-3 and 
EPHA7, MERTK, EPHA4, EGFR, IGF1R, and FGFR2 in BT474 are also upregulated, 
consistent with a transcriptional component of the adaptive RTK response. In BT474 cells, 
IRS2 and IGF1 (both 16-fold) are among the top 20 upregulated genes, indicating an 
autocrine/paracrine feedforward loop activating IGF1R signaling.
Significant heterogeneity exists among kinases that compensate for ERBB2 in the 
presence of lapatinib
Given the cluster of INSR/IGF1R activation, reports of IGF1R/ERBB2/ERBB3 complexes 
in trastuzumab-resistant cells (Huang et al., 2010), and the enrichment of glucose signaling 
networks from the RNAseq data, we investigated the role of IGF1R and INSR in bypassing 
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ERBB2 inhibition. SKBR-3 and BT474 cells were treated with increasing doses of the 
INSR/IGF1R inhibitor BMS754807 (BMS754) in the presence or absence of lapatinib 
(Figure 3A). The combination of lapatinib + BMS754 causes a dose-dependent increase in 
AKT phosphorylation in SKBR-3 but a decrease in BT474 cells. Combinations of lapatinib 
and BMS754 have little effect on HCC1419 and HCC1954 signaling (Figure S3F), but in 
MDA361 cells BMS754 alone reduces phosphorylation of ERBB2, ERBB3, FAK, SFKs, 
and AKT S473, and in combination with lapatinib further inhibits AKT (Figure 3B). Crystal 
violet colony formation assays demonstrate the combination of lapatinib and BMS754 
significantly inhibits growth of MDA361 cells, but resistant colonies persist, and no major 
enhancement of lapatinib-induced growth inhibition is observed in other cell lines (Figure 
3C). Thus, co-targeting ERBB2 and the common IGF1R/INSR response does not provide a 
successful pan combination therapy.
Lapatinib induces activity and transcription of DDR1, SFKs, and EPH receptors in multiple 
cell lines (Figures 2A, 2B, 2F), all of which are targets for dasatinib, and previous reports 
link SFKs to escape from ERBB2-targeted therapies (Rexer et al., 2011; Zhang et al., 2011). 
Treatment of SKBR-3 and BT474 cells with dasatinib causes a loss of MIB binding of 
multiple RTKs and TKs and prevents lapatinib-induced MIB-binding (Figure 3D). Colony 
formation assays demonstrate dasatinib only modestly enhances lapatinib growth-inhibition 
in BT474 and MDA361 cells (Figure 3C). Western blots indicate the combination of 
lapatinib and dasatinib inhibits activation of SFKs, AKT, and ERK1/2, but actually increases 
FAK phosphorylation (Figure 3E). Lapatinib induces FAK MIB-binding in multiple cell 
lines (Figure 2A), and the FAK inhibitor PF573228 in combination with lapatinib synergize 
in colony formation assays in SKBR-3 cells (Figure 3C). PF573228 inhibits FAK and SFK 
phosphorylation in the presence or absence of lapatinib (Figure 3F), suggesting both 
pathways must be inhibited in the presence of lapatinib to generate stable growth inhibition. 
While other cell lines do not demonstrate such strong synergism seen with SKBR-3 cells, 
FAK signaling is crucial for the growth of several cell lines and FAK inhibition enhances 
lapatinib growth inhibition.
FGFR2 is induced by lapatinib by MIB/MS (SKBR-3, Figure 2A) and RNAseq (BT474, 
Figure 2F), and FGFR2 has been implicated in compensating for ERBB2 in the presence of 
lapatinib (Azuma et al., 2011), so we tested lapatinib + a pan-FGFR inhibitor (BGJ398). 
Colony formation assays demonstrate FGFR inhibition enhances lapatinib growth-inhibition 
and SKBR-3 cells display moderate synergism between lapatinib and BGJ398 (Figure 3C). 
Most lines are growth-inhibited by BGJ398 in the absence of lapatinib, suggesting FGFRs 
cooperate with ERBB2 for growth of ERBB2+ cells. Combining lapatinib and BGJ398 
inhibits ERBB2/ERBB3 reactivation and further inhibits SFK and FAK phosphorylation in 
SKBR-3 cells, but in turn elicits a stronger AKT/ERK response than lapatinib alone (Figure 
3G). MIB/MS analysis of SKBR-3 cells demonstrates BGJ398 inhibits lapatinib induction of 
SFKs, FAK1/2, and multiple other TKs consistent with FGFR participation in lapatinib-
induced kinome adaptation (Figure 3H). The combination of lapatinib and BGJ398 still 
allows resistant colony formation in all five cell lines, suggesting alternative growth-
promoting signaling networks are activated even in response to combined ERBB/
FGFR/SFK/FAK inhibition. Overall, these results identify multiple kinases that contribute to 
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ERBB2+ cell growth, and reveal heterogeneity in the kinases that compensate for lapatinib-
mediated ERBB2 inhibition.
Lapatinib-resistant SKBR-3 and BT474 depend on multiple kinases for growth
To further define how the kinome bypasses inhibition of ERBB2, we generated lapatinib-
resistant (LapR) SKBR-3 by continuous treatment with 300nM lapatinib for 4+ months and 
LapR BT474 by progressively increasing doses of lapatinib every 3-4 weeks to 300nM. 
Resistant lines were kept as a pool of all clones that grew out. LapR SKBR-3 grow at a 
similar rate to parental cells while LapR BT474 grow somewhat slower than parental 
(Figures S4A-B). LapR cells are less sensitive to growth inhibition by ERBB2 knockdown 
but similarly sensitive to ERBB3 knockdown as compared to parental cells (Figure 4A). 
MIB/MS was used to compare LapR cells to lapatinib-sensitive parental cells (Figure S4C). 
Longtail plots of activated kinases show the most-activated kinases in LapR cells overlap 
with 48 h MIB/MS signatures and transcriptome responses of the parental line and other 
ERBB2+ lines (Figures 4B, 2A, 2F). LapR SKBR-3 and BT474 cells share several activated 
kinases, including PRKDC, CDK5, TGFR1, ACVR1, CK1/2 and TKs MET, DDR1, 
FGFR2, FRK, and FER. Among RTKs, LapR SKBR-3 display strong activation of ERBB3 
and modest increases in DDR1, FGFR2 and MET, while LapR BT474 activate multiple 
FGFRs, EPHA7, MERTK, MET, and IGF1R (Figure 4C). Western blots indicate inhibition 
of EGFR/ERBB2 phosphorylation in LapR cells with upregulation of multiple RTKs and 
reactivation of AKT/ERK in SKBR-3 cells but reduced activity of AKT/ERK in BT474 
relative to parental cells (Figure 4D). Knockdown of ERBB RTKs, FGFR2, DDR1, MET, 
and CDK5 all provided partial growth inhibition of LapR SKBR-3 cells, while LapR BT474 
cells are growth-inhibited by ERBB3, FGFR2, and CDK5 knockdown (Figures 4E, S4D-F). 
Thus, prolonged exposure to lapatinib causes a broad reorganization of the kinome and 
shifts dependency away from ERBB2 and toward multiple other kinases including several 
RTKs.
BET family bromodomain inhibition suppresses lapatinib-induced kinome reprogramming
By undertaking this comprehensive analysis, we unveiled significant heterogeneity in 
lapatinib-induced kinome adaptation in ERBB2+ cells and demonstrated the resiliency of the 
kinome to bypass combinations of lapatinib and a second kinase inhibitor. This argues 
multiple sequential combinations of kinase inhibitors and possibly intermittent therapies 
might be necessary to prevent resistance, but rationally choosing such a regimen poses a 
significant challenge. Multiple kinases contribute to growth, and since there is no one drug 
that can inhibit the activity of all responsive kinases, we hypothesized that targeting the 
adaptive response itself would make lapatinib-induced growth arrest more durable (Figure 
5A). RNAseq analysis indicates 8-10% of the expressed transcriptome is upregulated ≥2-
fold within 48 h of lapatinib treatment (Figure 2D). Of significance, kinases involved in 
resistance are transcriptionally induced by lapatinib treatment (e.g., ERBB3, DDR1, 
FGFR2), as are many kinases in the 48 h MIB/MS signature of SKBR-3 cells (Figure S5A). 
This is consistent with lapatinib inhibiting AKT and ERK signaling networks causing 
FOXO activation and c-Myc degradation, leading to RTK upregulation (Chandarlapaty et 
al., 2011; Duncan et al., 2012). Thus, we decided to target epigenetic factors – proteins that 
modify or associate with chromatin – to prevent the reprogramming response at a 
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transcriptional level. We tested inhibitors of different epigenetic enzymes and identified 
JQ1, an inhibitor of BET family bromodomains (Delmore et al., 2011) as capable of 
suppressing lapatinib-induced kinome reprogramming.
ERBB2+ cell lines are sensitive to growth inhibition by JQ1 and I-BET762, a second BET 
bromodomain inhibitor (Figure S5B). Treatment of SKBR-3 cells with JQ1 prevents 
lapatinib-induced phosphorylation and expression of ERBB3, a primary mediator of the 
adaptive response leading to AKT reactivation and lapatinib resistance (Figure 5B). JQ1 also 
suppresses lapatinib-induced expression of FGFR2, DDR1, IGF1R, pFAK, pSFK and 
pPKCδ across multiple cell lines (Figure 5C). JQ1 alone has little effect on AKT and p70 
S6K phosphorylation, but in combination inhibits the activity of both kinases more than that 
seen with lapatinib alone. Increased PARP cleavage is observed with the combination of 
lapatinib and JQ1 versus single agents, indicating an increase in apoptosis (Figure 5C). JQ1 
also inhibits lapatinib-mediated kinase induction in HCC1954 and MDA361 cells, including 
growth-promoting kinases FGFR1, FGFR2, and IGF1R (Figure S5C). Treatment of SKBR-3 
cells with another BET inhibitor, I-BET151, similarly blocks lapatinib-induced expression 
and phosphorylation of signature kinases (Figure S5D). Quantitative RT-PCR analysis 
demonstrates JQ1 suppresses or prevents lapatinib-induced transcription of many adaptive 
response kinases implicated in resistance, including ERBB3, DDR1, FGFR2, IGF1R, and 
MET, in addition to ERBB2 itself (Figures 5D and S5E).
JQ1 alone only reduces the growth of SKBR-3 and BT474 cells and results in the formation 
of resistant colonies in four-week clonogenic assays, but when combined with lapatinib 
strongly arrests growth or results in regression of cell number and essentially eliminates 
colony formation (Figures 5E, 5F). I-BET762 and I-BET151 elicit similar growth-inhibitory 
responses from SKBR-3 and BT474 cells (Figures S6A-C). Clonogenic assays with 
HCC1419 cells demonstrate combinations of lapatinib and BET bromodomain inhibitors 
suppress ERBB2+ cell growth more effectively than kinase inhibitor combinations with 
lapatinib (dasatinib, BMS754, PF228, and BGJ398) (Figure 5G). Growth of HCC1954 and 
MDA361 cells, which are more resistant to lapatinib than SKBR-3 or BT474 cells, is also 
inhibited by lapatinib + BET bromodomain inhibitors in 8-day and 5-week growth assays 
(Figures S6D-F).
Since AKT is a convergent node downstream of many RTKs and crucial to ERBB2+ cell 
growth, we compared BET bromodomain inhibitors to AKT inhibitors in combination with 
lapatinib. In 8-day treatments of BT474 cells, the AKT inhibitor MK2206 alone or in 
combination with lapatinib induces multiple RTKs (ERBB3, DDR1, IGF1R, FGFR2) and 
results in increased FAK, SFK, and ERK phosphorylation (Figure 5H). Importantly, JQ1 or 
I-BET151 alone is unable to completely suppress signature kinase expression and signaling, 
and only when combined with lapatinib inhibits RTK expression and activity and causes a 
loss of downstream FAK, SFK, AKT, ERK, and p70 S6K signaling (Figures 5H, S6G). This 
strongly suggests JQ1 inhibits reactivation of oncogenic signaling by suppressing the 
adaptive kinome response. 4-week growth assays indicate that while AKT inhibitors 
(MK2206 and GSK690693) work well in combination with lapatinib in BT474 cells, 
resistant colonies still form in SKBR-3 and HCC1419 cells (Figure S6H). This contrasts 
with the lack of colony formation in lapatinib + JQ1 combinations across all lines. These 
Stuhlmiller et al. Page 8













findings further support disruption of AKT/ERK signaling networks leading to RTK 
upregulation and a sustained blockade of the adaptive response by BET bromodomain 
inhibition.
JQ1 regulates lapatinib-induced transcription and releases BRD4 and pSer2-Polymerase II 
from adaptive kinase genes
RNAseq analysis demonstrates JQ1 downregulates 8% and 11% of genes at least 2-fold in 
SKBR-3 and BT474 cells, respectively (Figures 6A and S7A). A smaller percentage is 
upregulated 2-fold, with 3% in SKBR-3 and 5% in BT474, indicating JQ1 affects 
transcription overall less than lapatinib. In combining lapatinib and JQ1, we found that 
genes upregulated by lapatinib were suppressed by JQ1 more than those unaffected or 
downregulated by lapatinib (Figures 6B-E, S7B-E). Of transcripts induced at least 2-fold by 
lapatinib in SKBR-3 cells, adding JQ1 suppressed the induction of 27% by at least half, and 
further upregulated just 4% (Figure 6C). Similarly, in BT474 cells JQ1 suppresses 28% of 
lapatinib-induced genes (Figure S7C). This indicates that JQ1 preferentially modulates 
lapatinib-responsive gene expression. Reports indicate suppression of MYC transcription is 
central to JQ1 function. BT474 cells stably overexpressing c-Myc are less sensitive to JQ1, 
but the combination of lapatinib+JQ1 still causes growth arrest in SKBR-3 and cell 
regression in BT474 despite the rescue of c-Myc levels (Figures S7F-G).
RNAi was used to inhibit the expression of BET family members BRD2, 3 or 4 in SKBR-3 
and BT474 cells (Figures 6F, S7H-I). BRD2 and BRD3 knockdown actually increases target 
kinase transcription in response to lapatinib. In contrast, lapatinib in combination with 
BRD4 knockdown was similar to JQ1 in reducing lapatinib-mediated induction of ERBB3 
and DDR1 expression. Chromatin immunoprecipitation (ChIP)-PCR demonstrates JQ1 
displaces BRD4 from the promoters and upstream elements of lapatinib-induced kinase 
genes ERBB2, ERBB3, FGFR2, and DDR1 (Figures 6G, S7J). KIT is not expressed in 
SKBR-3 cells and serves as a negative control for ChIP-PCR analysis. JQ1 treatment also 
reduces the level of the elongating form of RNA Polymerase II (phospho-Serine 2 of the C-
terminal tail repeat; pS2-Pol2) binding to promoters and internal exons of target kinase 
genes, consistent with transcriptional inhibition (Figures 6G, S7J). Importantly, BRD4 and 
pS2-Pol2 are most effectively dissociated from chromatin by combined lapatinib + JQ1 
treatment, indicating synergism between these drugs at an epigenetic level.
BET bromodomain inhibition re-sensitizes resistant cells to lapatinib
RNAseq of LapR SKBR-3 cells following 8-day treatment with combinations of lapatinib 
with JQ1 or I-BET151 indicates transcriptional suppression of a large proportion of TKs, 
including those that contribute to growth (ERBB3, DDR1, FGFR2, and MET, Figure 7A). 
Many outlier kinases from PCA (a representation of heterogeneity in the kinome response, 
Figure 2C) are also suppressed by BET bromodomain inhibition (Figure 7B). MIB/MS 
analysis from the same treatments indicates JQ1 and I-BET151 inhibit or block the activity 
of the most-induced kinases in LapR SKBR-3 cells relative to parental cells (Figure 7C). 
Accordingly, JQ1 and I-BET151 inhibit the protein expression and phosphorylation of 
signature kinases in LapR SKBR-3 and BT474 cells, effectively reversing the adaptive 
kinome reprogramming response (Figure 7D). Four-week clonogenic growth assays 
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demonstrate that the combination of lapatinib and JQ1 arrests the growth of lapatinib-
resistant cells (Figure 7E). Furthermore, combinations of lapatinib and BET bromodomain 
inhibitors are superior to combinations of lapatinib and kinase inhibitors that only slow the 
growth of LapR cells (Figure 7F). Lapatinib + BET bromodomain inhibitor combinations 
are even significantly more effective than the triple combination of lapatinib, dasatinib and 
FAK inhibitor. This indicates that arresting the transcriptional reprogramming response is 
more effective than inhibiting the activity of multiple induced kinases. While BET inhibitors 
arrest the growth of LapR cells in combination with lapatinib, removal of lapatinib from the 
media while maintaining JQ1 or I-BET762 in the culture allows the cells to begin growing 
again (Figure 7G). Thus, lapatinib and BET bromodomain inhibitor must be present in 
combination to effectively inhibit growth; JQ1 or I-BET alone is not sufficient to inhibit 
growth of the cells. Since LapR BT474 cells do not depend on EGFR or ERBB2 for growth 
in the presence of lapatinib (Figure 4A), this indicates BET bromodomain inhibitors 
sensitize cells to lapatinib by blocking alternative kinases involved in adaptive growth 
responses.
DISCUSSION
In this study we used MIB/MS to define lapatinib-induced kinase activation dynamics on a 
kinome-wide level. This global approach unveiled a robust network of kinases that 
compensate for ERBB2 inhibition induced within 48 h of lapatinib treatment, indicating 
multiple potential mechanisms of resistance emerge rapidly upon kinase inhibitor treatment. 
Inhibition of different induced kinases in combination with lapatinib increased growth 
inhibition across the five ERBB2+ cell lines to varying degrees. Strong growth inhibition 
was observed by targeting FAK in combination with lapatinib in SKBR-3 cells, indicating 
significant synergism can be achieved if such vulnerable nodes are defined. Heterogeneity in 
the adaptive kinome response, however, makes identifying effective combination inhibitor 
treatments a challenging task. Adding to the problem is the differential dependence of tumor 
cells on unrelated kinases in addition to ERBB2. Together, these findings present a dilemma 
where combinations of any two or even three kinase inhibitors would be insufficient to 
suppress the resiliency of the kinome and sustain inhibition of tumor cell growth.
The five cell lines used in our study are each ERBB2+ but HCC1954 and MDA361 are less 
sensitive to lapatinib than the other three lines. MDA361 cells respond to inhibitors of 
IGF1R/INSR, SFKs, FAK, and FGFRs in the absence of ERBB2 inhibition, suggesting 
intrinsic resistance to ERBB2-targeted therapies can be rooted in dependence on multiple 
alternative kinases. Successful treatment of such tumors would be difficult with 
combinations of kinase inhibitors. Heterogeneity of kinase expression in different regions of 
the tumor would further enhance this dilemma. Our study demonstrates BET bromodomain 
inhibition provides an epigenetic mechanism to target a series of kinases that mediate 
resistance and sustain ERBB2+ cell growth. Indeed, MDA361 cells are the most sensitive to 
the JQ1/lapatinib combination treatment even though they are relatively insensitive to 
lapatinib alone.
We acknowledge inhibition of major epigenetic regulators such as BET bromodomain 
proteins has effects beyond the blockade of adaptive kinome reprogramming. Histone 
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deacetylase inhibitors such as panobinostat are in clinical use and have been shown in 
melanoma to suppress resistance mechanisms to BRAF inhibition (Johannessen et al. 2013). 
We found panobinostat similarly blocks adaptive reprogramming in ERBB2+ breast cancer 
cells, but it also displays significant cellular toxicity in the absence of lapatinib. In contrast, 
we identified a significant molecular synergism between BET bromodomain inhibitors and 
lapatinib that inhibited RNA polymerase II function, kinase expression and phosphorylation. 
The ChIP-PCR data with SKBR-3 and long-term signaling studies with BT474 indicate the 
combination of lapatinib and BET bromodomain inhibitors is required to substantially 
suppress transcription of RTKs and prevent reactivation of AKT/p70 S6K signaling. These 
effects are not observed by JQ1 or I-BET151 treatment alone and suggest BET 
bromodomain inhibitors target the epigenetic machinery involved in the adaptive 
reprogramming response to lapatinib. RNAseq indicates approximately 2000 expressed 
genes are up or down regulated two-fold or greater by lapatinib. This adaptive transcriptome 
response involves a global reorganization of signaling that is borne out by significant 
changes in kinome activation dynamics. This argues that targeting broad-acting epigenetic 
regulators of transcription like BET bromodomain proteins is not only advantageous but 
needed to suppress this dramatic induction of gene expression. JQ1 suppresses 27% of 
lapatinib-induced transcripts by at least half, in contrast to 8% of genes as a whole. JQ1 thus 
has a selective inhibition of lapatinib-induced transcripts. SiRNA experiments identified 
BRD4 as participating in the reprogramming response. BRD4 is a core component of the P-
TEFb transcriptional elongation complex (Jang et al., 2005; Yang et al., 2005), and regulates 
the phosphorylation of RNA polymerase II for activation of transcriptional elongation of 
newly induced genes (Devaiah et al., 2012). Disruption of this complex by targeting BRD4 
function provides an elegant mechanism of how BET bromodomain inhibition might 
regulate kinome reprogramming.
By targeting chromatin readers we suppress expression of the majority of kinases having a 
potential role in lapatinib resistance, and provide a method to address both the heterogeneity 
in kinome response and inhibit a broad panel of kinases known to drive ERBB2+ cancer cell 
growth. Recent studies have described similar RTK networks comprised of ERBB receptors, 
MET, IGF1R, and FGFRs that become upregulated after targeted RTK inhibition (Singleton 
et al., 2013; Zhang et al., 2014). It is conceivable that BET bromodomain inhibition would 
suppress these kinases in other cancers as well and provide a means to block the adaptive 
response to EGFR and FGFR inhibition observed in these studies. We believe epigenetic 
enzyme-targeting drugs will be key to preventing resistance rooted in kinome 
reprogramming, thus making the action of kinase inhibitors durable. With at least four BET 
bromodomain inhibitors in clinical trials, testing of a BET bromodomain inhibitor to block 
adaptive responses induced with kinase inhibitors is a possibility.
EXPERIMENTAL PROCEDURES
MIB Chromatography and LC/MS
MIB preparation and chromatography was performed as previously described (Duncan et al., 
2012). For multiplexing, peptides were labeled with iTRAQ and separated on a 288 or 300 
min 5-45% ACN gradient as a single fraction. ABSciex 5800 MALDI TOF/TOF and 
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Thermo Q-Exactive ESI mass spectrometers were used. For details, see supplemental 
experimental procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Lapatinib induces dynamic kinome responses
(A) Flow chart for experimental design.
(B) MIB/MS kinome activation dynamics over 48 h of 300nM lapatinib treatment in 
SKBR-3 cells. Ratios greater than 1 indicate increased MIB-binding (increased activity) and 
values less than 1 indicate decreased MIB-binding (decreased activity) relative to control 
cells treated with DMSO. Data presented is the average of four biological replicates.
(C) MIB-binding dynamics suggest reactivation of ERBB2 in SKBR-3 cells but continued 
suppression in BT474 cells.
(D) Hierarchical clustering of MIB-binding ratios in SKBR-3 cells identifies clusters of 
dynamic kinase behavior.
(E) Dynamics of a select set of kinases illustrates multiple behaviors in response to lapatinib. 
Four points graphically indicate 0, 4, 24, and 48 h MIB-binding. Blue, inhibited; red, 
activated.
(F) Western blots validate MIB/MS results and identify upregulation of ERBB3, DDR1, 
FRK, and PKCδ and increased activation of FAK, SRC family kinases (SFKs), and STAT3 
in response to lapatinib. AKT and ERK1/2 are inhibited at 4 h but become reactivated over 
72 h. Treatment with 1µM lapatinib re-inhibits EGFR and ERBB2 but has little effect on 
other kinases.
(G) BT474 MIB-binding dynamics of tyrosine kinases and MEK/ERK and AKT/mTOR 
pathways.
(H) Western blots indicate upregulation of ERBB3, INSR, and IGF1R total levels and 
increase in SFK phosphorylation after lapatinib treatment in BT474 cells.
Also see Figures S2
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Figure 2. MIB/MS and RNA sequencing define heterogeneity in the adaptive response
(A) Statistically significant MIB-binding changes after 48 h lapatinib treatment based on 
Benjamini-Hochberg adjusted p-values at FDR of 0.05 and standard deviation in five 
ERBB2+ cell lines depicted graphically. Kinome trees reproduced courtesy of Cell 
Signaling Technology, Inc. (www.cellsignal.com).
(B) Lapatinib-induced MIB-binding changes of tyrosine kinases illustrates differences 
between cell lines and identifies common response of INSR and IGF1R activation.
(C) Principal component analysis identifies kinases that drive the variation in kinome 
response. Kinases captured in at least 3 out of 4 MIB/MS runs per cell line (67 kinases) were 
used.
(D) Lapatinib induces 2-fold changes up or down in 18-20% of expressed mRNA 
transcripts.
(E) Gene ontology terms enriched in commonly upregulated mRNAs between SKBR-3 and 
BT474 cells ide ntifies glucose regulation and transcriptional regulation as most significant 
processes.
(F) Kinase mRNAs upregulated by lapatinib at least 2-fold by RNAseq in SKBR-3 and 
BT474. Hatched bars indicate RTKs and red bars indicate common upregulated kinases.
Also see Figures S2 and S3
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Figure 3. Cell lines exhibit variability in kinases that drive growth in the presence and absence of 
lapatinib
(A) Lapatinib combined with increasing doses of BMS754807 (IGF1R/INSR inhibitor) 
causes an increase in AKT phosphorylation in SKBR-3 but a decrease in BT474 relative to 
lapatinib treatment alone after 24 h.
(B) BMS754 inhibits ERBB2/3 phosphorylation as a single agent, and when combined with 
lapatinib causes a further inhibition of AKT phosphorylation after 24 h.
(C) Colony formation assays indicate heterogeneity in the kinases that contribute to growth. 
IGF1R/INSR inhibition has an additive effect with lapatinib in MDA361. Dasatinib is 
additive in BT474 and MDA361 but does not significantly enhance growth inhibition of 
other lines. SKBR-3 cells display synergism between lapatinib and PF228 (FAK inhibitor) 
or BGJ398 (FGFR inhibitor) but other cell lines show varying degrees of growth-inhibition 
by FAK or FGFR inhibition alone and in combination with lapatinib. SKBR-3, BT474, and 
HCC1419 treated for 4 weeks, HCC1954 and MDA361 treated for 5 weeks. Lapatinib 
doses: 100nM SKBR3; 30nM BT474; 10nM HCC1419; 300nM HCC1954 and MDA361. 
Data presented is mean ± SD of three technical replicates. * indicates significant difference 
from lapatinib alone (p≤0.05).
(D) MIB/MS profile of SKBR-3 and BT474 cells after 48h treatment with 300nM Lapatinib, 
30nM Dasatinib, or the combination. Dasatinib inhibits MIB-binding of multiple tyrosine 
kinases, but not FAK1 and FAK2 in SKBR-3 cells.
(E) Western blots after 48 h demonstrate Dasatinib inhibits Lapatinib-induced SFK 
phosphorylation but increases FAK phosphorylation.
(F) Western blots after 48 h indicate PF228 inhibits FAK and SFK phosphorylation, but 
increases AKT and ERK1/2 phosphorylation.
(G) Western blots indicate FGFR inhibition alone slightly reduces AKT and ERK 
phosphorylation at 4 h, but elicits strong reactivation by 48 h. Combination with lapatinib 
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indicates FGFRs regulate ERBB signaling and SFK and FAK phosphorylation. 300nM 
Lapatinib and 300nM BGJ398 added directly to media at 0 h. Media was not changed 
throughout experiment.
(H) MIB/MS analysis of 300nM lapatinib, 300nM BGJ398, or the combination after 48 h 
indicates FGFRs regulate multiple lapatinib-induced TKs.
(I) Matrix of p-values comparing growth inhibition of lapatinib alone versus lapatinib + 
kinase inhibitor in colony formation assays. Red, significant (p≤0.05); blue, not significant 
(p≥0.05).
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Figure 4. Multiple unrelated kinases contribute to the growth of lapatinib-resistant cells
(A) Parental or 300nM lapatinib-resistant (LapR) SKBR-3 and BT474 cells were transfected 
with siRNAs against GAPDH (control) or ERBB receptors and cultured for 96 h. Both 
parental lines are strongly growth-inhibited by ERBB2 and ERBB3 knockdown. LapR cells 
are less dependent on ERBB2 but remain similarly dependent on ERBB3.
(B) MIB/MS long tail plots of most-activated kinases in LapR SKBR-3 and BT474 cells, 
relative to parental cells. Kinases in red are commonly over-activated in SKBR-3 and 
BT474.
(C) MIB/MS profile of tyrosine kinases from LapR SKBR-3 and BT474 cells. LapR 
SKBR-3 cells display enhanced MIB-binding of ERBB3, DDR1, FGFR2, MET, FRK, and 
SRC. LapR BT474 have increased activity of multiple FGFRs, EPHA7, IGF1R, MERTK, 
MET, LYN, and FAK1. Data presented is mean of two biological replicate MIB/MS 
experiments.
(D) Western blots indicate RTK upregulation in LapR SKBR-3 cells and reactivation of 
AKT/ERK signaling. LapR BT474 cells display suppressed activity of AKT and ERK 
relative to parental cells. P, parental; R, LapR.
(E) 96 h siRNA knockdown in LapR SKBR-3 cells indicates slight dependency on ERBB 
family, and a stronger dependency on DDR1, FGFR2, and CDK5. BT474 cells are growth-
inhibited by ERBB3, FGFR2, and CDK5 knockdown. Data presented in A and E is mean ± 
SD of six technical replicates.
Also see Figure S4
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Figure 5. BET bromodomain inhibition suppresses lapatinib-induced kinome reprogramming 
and arrests growth
(A) Kinome reprogramming leads to transcriptional upregulation of multiple alternative 
kinases capable of reactivating or bypassing ERBB2-directed signaling. We hypothesize by 
inhibiting the BET family of bromodomain-containing acetylation readers, we can prevent 
the adaptive response at an epigenetic level.
(B) Western blots demonstrate JQ1 (BET family bromodomain inhibitor) suppresses 
lapatinib-induced ERBB3 phosphorylation and expression at 300nM, and inhibits 
reactivation of AKT in SKBR-3 cells. 48h treatments.
(C) Western blots indicate JQ1 blocks protein expression of multiple kinases involved in 
lapatinib resistance, and leads to a decrease in ERBB family, SFK, FAK, and PKCδ 
phosphorylation. JQ1/lapatinib combinations inhibit AKT and p70 S6K phosphorylation 
more than Lapatinib alone and increase cleavage of PARP. 48h treatments.
(D) qRT-PCR after 24h treatment shows JQ1 inhibits mRNA transcription of multiple RTKs 
involved in resistance (ERBB3, DDR1, FGFR2, MET) and suppresses lapatinib-mediated 
induction.
(E) 8-day growth curves demonstrate JQ1/lapatinib combination prevents growth of 
SKBR-3 and BT474 cells. Data presented is mean ± SD of six technical replicates.
(F) JQ1 in combination with lapatinib suppresses colony formation of SKBR-3 and BT474 
cells after 4-weeks.
(G) BET family bromodomain inhibitors (JQ1, I-BET762, I-BET151) suppress colony 
formation of HCC1419 cells more so than kinase inhibitors in combination with lapatinib in 
4-week colony formation assays.
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(H) Western blots indicate AKT inhibition (MK2206) induces RTK expression and ERK 
signaling alone and in combination with lapatinib. BET bromodomain inhibition alone does 
not sustain inhibition of signature kinases, and only in combination with lapatinib suppresses 
the adaptive response. 8-day treatment with 30nM lapatinib, 100nM MK2206, and 300nM 
JQ1.
Data presented in D, F, and G is mean ± SD of three technical replicates. Also see Figures 
S5 and S6
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Figure 6. JQ1 modulates lapatinib-induced transcription and inhibits epigenetic regulation of 
signature kinase genes
(A) RNAseq indicates JQ1 affects 11% of expressed genes 2-fold or more in SKBR-3 cells 
after 48 h treatment.
(B) Figures 6C-E refer to JQ1 effect on lapatinib-regulated genes as indicated.
(C) JQ1 downregulates 27% of the 1009 lapatinib-induced genes by at least 2-fold from the 
lapatinib-induced mRNA level.
(D) 1000 genes not affected by lapatinib treatment display a similar up- or down-regulation 
profile in the lapatinib+JQ1 combination compared to JQ1 alone.
(E) 964 genes at least 2-fold downregulated by lapatinib are mostly unaffected by JQ1 as 
compared to JQ1 alone or JQ1 effects on lapatinib-upregulated genes.
(F) qRT-PCR demonstrates siRNA-mediated knockdown of BRD2 and BRD3 enhances 
transcription of ERBB2, ERBB3, FGFR2 and DDR1. Knockdown of BRD4 suppresses 
ERBB3 and DDR1 transcription, similar to JQ1. 24h siRNA knockdown, then 24h drug 
treatment; 300nM JQ1, 300nM lapatinib. Data presented is mean ± SD of three technical 
replicates.
(G) ChIP-PCR indicates JQ1 inhibits BRD4 promoter occupation in the absence of lapatinib. 
Loss of BRD4 and elongating RNA Polymerase II (pS2-Pol2) from upstream elements is 
maximal when JQ1 is combined with lapatinib. 4h treatments with 300nM lapatinib and 
300nM JQ1 in SKBR-3 cells. Data presented is mean of three biological replicate 
experiments.
Also see Figure S7
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Figure 7. BET bromodomain inhibition suppresses signature kinases and arrests growth in 
lapatinib-resistant cells
(A) RNAseq after 8-day treatment of lapatinib-resistant (LapR) SKBR-3 cells with lapatinib 
+ 300nM JQ1 or 1µM I-BET151 indicates transcriptional suppression of the majority of 
tyrosine kinases.
(B) mRNA fold changes in outlier kinases identified by PCA (Figure 2C) indicates BET 
inhibitors suppress the majority of kinases that drive variation in the kinome response.
(C) MIB/MS analysis of the top 20 most-activated kinases in LapR SKBR-3 cells following 
8 days treatment with 300nM JQ1 or 1µM I-BET151 indicates the majority of kinase 
activity is inhibited or blocked.
(D) Western blots of LapR SKBR-3 and BT474 cells treated with 300nM JQ1 or 1µM I-
BET151 in combination with 300nM lapatinib show suppression of signature kinase 
expression and phosphorylation.
(E) 4-week colony formation assays demonstrate JQ1 suppresses colony formation and 
arrests growth of LapR SKBR-3 and BT474 cells in the presence of lapatinib. Data 
presented is mean ± SD of three technical replicates.
(F) LapR BT474 cells are moderately growth-inhibited by combinations of lapatinib and 
other kinase inhibitors, but growth is completely suppressed by lapatinib and bromodomain 
inhibitors (300nM JQ1, 1µM I-BET762, or 1µM I-BET151, even more effectively than a 
triple kinase inhibitor combination (lapatinib+dasatinib+PF228).
(G) Growth of LapR BT474 cells is arrested with 300nM JQ1 or 1µM I-BET762, but only in 
the presence of lapatinib.
Data presented in F and G is mean of six technical replicates ± SD.
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